Overview

A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide